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Summary: In the present study we investigated the nature of somatoliberin-like immunoreactivity in human
seminal plasma. In unextracted seminal plasma, somatoliberin-like immuno reactivity represented 3.8 §/1
somatoliberiii, with a dilution curve that ran almost completely parallel to that of synthetic somatoliberin
standard. After extraction by adsorption on hydrophobic CIS Sep-pak cartridges or immunoaffmity chro-
matography, no somatoliberin-like immunoreactivity in seminal plasma could be detected. After gel permeation
chromatography on a Sephadex G-50 fine column, all somatoliberin-like immunoreactivity of unextracted
seminal plasma was recovered at the void volume of the column. When equal volumes of unextracted seminal
plasma and radioiodinated somatoliberin were coincubated for two days at 4 °C, gel chromatography revealed
the disappearance of the normal [J?5I]somatoliberin peak, replaced by a new peak eluting shortly after the
total volume of the column. When unextracted seminal plasma was heated at 90 °C for 10 min or submitted
to ultrafiltration, the interfering factor was no longer detectable. Our data show that enzymic degradation of
radioiodinated somatoliberin led to misleadingly high concentrations of somatoliberin-like immunoreactivity
in seminal plasma. These phenomena should therefore be considered when performing radioimmunoassays
of short chain peptides in biological fluids.
Introduction
Somatoliberin was first isolated from two pancreatic
islet cell tumours (1,2), and subsequently from normal
human hypothalämus (3). Using immunohistochem-
ical and radioimmunoassay techniques, somatoliberin
has been mainly localized in the infundibular region
of the hypothalämus (4). Only picomol quantities of
somatoliberiii are present in the hypothalämus (4),
but somatoliberin has also been detected in other
areas of human brain and gut (5, 6). Occurrence at
extrahypothalamic sites has also been reported for
other known hypothalamic hypophysiotropic hor-
mones (7). Moreover, most hypothalamic hormones
have been shown to possess biological activities in-
dependent of pituitary regulation (8). Somatoliberin
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also has been found to stimulate enzyme secretion of
the exocrine pancreas (9).
Peptide hormones have been found in seminal plasma
of normal subjects (10), but the physiological signif-
icance of this finding is unknown. In the present study
we investigated and characterized the presence of im-
munoreactive somatoliberin in human seminal
plasma.
Materials and Methods
Seminal plasma
A pool of seminal plasma was obtained from the department
of andrology of the University of Munich. Semen samples were
collected into a plastic container by masturbation and were
delivered to the laboratory within 2 h. The pool of seminal
plasma, obtained by mixing different specimens, was centri-
fuged at 1600 g for 10 min and the supernatant was aliquoted
into 1 ml plastic vials, which were stored at —20 °C until use.
Semen sample aliquots were thawed at room temperature before
recentrifugation at 1600# for 10 min to remove cellular debris.
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Somatoliberin radioimmunoassay
Somatoliberin was measured using a specific antiserum raised
in rabbits immunized with synthetic Somatoliberin \ —44 cou-
pled to bovine thyroglobulin. This antibody is directed against
the C-terminal region of Somatoliberin and binds equally, on a
equimolar basis, to Somatoliberin 1—44, Somatoliberin 1—40,
and Somatoliberin 1—29 (11). Somatoliberin was radioiodi-
nated by the chloramine T method and purified by a two step
Chromatographie procedure: The tracer was initially applied to
a Sephadex G-10 column (1 χ 10 cm; Pharmacia, Uppsala,
Sweden) and eluted in acetic acid 0.1 mol/1 + bovine serum
albumin 1 g/1. The first peak, containing iodinated proteins,
was collected and applied to a Sephadex G-50 fine column
(1 χ 56 cm; Pharmacia, Uppsala, Sweden) and eluted with the
same buffer as above. The descending part of the second peak,
showing the highest binding to Somatoliberin antiserum, was
pooled and diluted in radioimmunoassay buffer (Na2HPO4
0.063 mol/1 and Na2EDTA 0.013 mol/1, pH 7.4, containing
bovine serum albumin 1 g/1, NaN3 0.2 g/1, Triton X-100 1 ml/1,
and aprotinin (Trasylol®, 400 000 Kallikrein inhibitory units/1)
at a concentration of about 5000 counts per minute. Somato-
liberin tracer was stored frozen at —20 °C until use. Standards,
diluted in radioimmunoassay buffer, or unknown samples (0.1
ml) were incubated in polypropylene tubes with 0.1 ml anti-
serum, diluted 1: '80 000 in radioimmunoassay buffer, for two
days at 4 °C. After addition of Somatoliberin tracer, containing
7 g/1 rabbit γ-globulins, incubation was continued for one day
at 4 °C. Antibody-bound and free Somatoliberin were separated
by a double antibody procedure, using 0.1 ml goat antirabbit
antiserum diluted 1:60 with radioimmunoassay buffer.
Gel chromatography
One-mi samples were separately applied to a Sephadex G-50
fine column (1 χ 56 cm), equilibrated, then eluted with radioim-
munoassay buffer. Samples and calibration standards (125I,
[usl]somatoliberin, and [12SI]thyroglobulin) were eluted at 4 °C
at a flow rate of 15 ml/h. One-mi fractions were collected and
kept frozen at —20 °C until assayed or, in case of radioiodinated
substances, directly counted in a gamma-counter.
Affinity chromatography of Somatoliberin
The γ-globulin fraction of antiserum K1783 was purified on a
Protein-Α Sepharose column (Pharmacia, Uppsala, Sweden).
Absorbed γ-globulins were eluted with acetic acid 0.1 mol/1 and
immediately desalted on a Sephadex G-25 column (1x12 cm)
equilibrated in Na-borate-HCl 0.01 mol/1 buffer, pH 8.7, γ-
globulins were conjugated to 4B-CNBr activated Sepharose
(Pharmacia, Uppsala, Sweden) following the-procedure sug-
gested by the manufacturer. A 0.5 χ 1 cm column was prepared
with the immunoadsorbent and equilibrated with radioimmu-
noassay buffer. Samples were diluted 3-fold with radioimmu-
noassay buffer and successively applied to the immunoaffinity
column. The column was washed with 10 ml radioimmunoassay
buffer and the antibody-bound Somatoliberin was eluted with
acetic acid 0.5 mol/1 containing bovine serum albumin 1 g/1.
After lyophilization, samples were reconstituted with radioim-
munoassay buffer before assay.
Somatoliberin extraction
The extraction method of Frohtnan et al. (12) was used with
minor modifications. Briefly, 1 ml of seminal plasma was di-
luted with 2 ml trifluoroacetic acid 0.01 mol/1 and applied onto
hydrophobic C 18 Sep-pak cartridges (Waters Associates, Mil-
lipore Corp., Milford, USA) previously activated by successive
applications of trifluoroacetic acid 0.01 mol/1, acetonitrile (vol-
ume fraction 0.8) in trifluoroacetic acid 0.01 mol/1, and trifluo-
roacetic acid 0.01 mol/1 again. The column was then washed
with 10 ml trifluoroacetic acid 0.01 mol/1 and eluted with
acetonitrile (volume fraction 0.8) in trifluoroacetic acid 0.01
mol/1. The eluate was lyophilized and then reconstituted in
radioimmunoassay buffer before being assayed.
Results
The detection limit of the assay (defined as the small-
est detectable concentration of ligand at 3 standard
deviations from 0 hormone concentration) was
50-70 ng/1 and 50% binding occurred at 400 — 500
ng/1. Extraction of radioiodinated Somatoliberin by
affinity chromatography or adsorption onto Sep-pak
CIS cartridges yielded a mean recovery of 78.3
± 3.5% and 87.1 ± 2.3% (± SE), respectively. Unex-
tracted seminal plasma contained 3.8 μ§/1 somatoli-
berin like-immunpreactivity at 50% binding of the
standard curve. The dilution curve of unextracted
seminal plasma ran parallel to the standard curve,
though a slight deviation to the left occurred at the
highest dilutions (fig. 1). However, no detectable
amount of Somatoliberin (< 50 ng/1) was measured
after extraction by affinity chromatography or acl·
sorption onto C 18 Sep-pak cartridges. On the other
hand, the Somatoliberin immunoadsorbent column
and the C18 Sep-pak cartridge did not retain the
somatoliberin-like immunoreactivity of seminal
plasma, since after adsorption to the column and
cartridge elevated levels of somatoliberin-like immu-
noreactivity could still be detected (< 2.5 μg/l) in the
effluent.
Following gel permeation chromatography, the so-
matoliberin-like immunoreactivity in seminal plasma
did not coelute with Somatoliberin standard and
tracer, but appeared in the void volume of the column
(fig. 2). Twenty-five ng Somatoliberin 1 —44 in 0.5 ml
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Fig. 1. Radioimmunoassay of unextracted seminal plasma. Di-
lution curves for synthetic Somatoliberin 1 -44 (D-D)
and unextracted seminal plasma (β—Β) are shown.
B/Bo, bound to maximum bound ratio.
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Fig. 2. Sephadex G-50 fine chroinatography of unextracted
seminal plasma (β—·) and of 25 ng synthetic somato-
liberin 1 -44 (D-D) incubated at 4 °C for two days in
1 ml unextracted seminal plasma. Samples were eluted
with radioimmunoassay buffer. Aliquots of the 1 ml
fractions were assayed for Somatoliberin by radioim-
munoassay. The column void volume (V0), total volume
(Vt), and elution position of synthetic Somatoliberin are
indicated by the arrows.
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Fig. 3. Sephadex G-50 fine chromatography of
[125I]somatoliberin after two days incubation at 4 °C
with either unextracted seminal plasma (α—α) or assay
buffer (π —α). Samples were eluted with radioimmu-
noassay buffer. The 1 ml fractions were directly counted
in a gamma-counter. The column void volume (V0),
total volume (Vt), and elution position of synthetic
Somatoliberin are indicated by the arrows.
radioimmunoassay buffer was incubated with 0.5 ml
unextracted seminal plasma at 4 °C for two days, in
order to reproduce the conditions of our somatoli-
berin radioimmunoassay. At the end of the incubation
period the mixture was chromatographed on the
Sephadex G-50 column, then fractions were measured
in radioimmunoassay. Control experiments for the
recovery of Somatoliberin standard following gel
chromatography were performed by incubating 25 ng
Somatoliberin standard in 1 ml radioimmunoassay
buffer for two days at 4 °C before chromatography,
and 25 ng Somatoliberin standard in 0.5 ml radioim-
munoassay buffer mixed with 0.5 ml seminal plasma
just before gel permeation. As shown in figure 2 only
a trace amount of Somatoliberin standard was re-
covered in the position where Somatoliberin standard
eluted. Aside from a small peak near the void volume
of the column, no other peak of somatoliberin-like
immunoreactivity was found. The recovery of soma-
toliberin standard incubated in radioimmunoassay
buffer alone was 88.5%, whereas, after two days in-
cubation in seminal plasma only 4.6% of added so-
matoliberin standard was recovered at the correct
elution position; on the other hand, immediate chro-
matography, without incubation of Somatoliberin
standard mixed with seminal plasma, resulted in a
minimal loss of recovered Somatoliberin (71.9%). The
anomalous, peak at the void volume of the column
was still present.
To further investigate the nature of this nonspecific
effect, Somatoliberin tracer and unextracted seminal
plasma were incubated together at 4 °C for two days.
As shown in figure 3, this procedure resulted in an
almost complete degradation of labelled somatoli-
berin with generation of a new peak of radioactive
material eluting shortly after the total volume of the
column. Numerous attempts were made to eliminate
this degradative enzymic activity, e. g. by addition of
enzyme inhibitors to seminal plasma before incuba-
tion with labelled Somatoliberin. Aprotinin, phenyl-
methylsulphonyl fluoride, and bacitracin did not,
however, prevent Somatoliberin tracer degradation.
Aliquots of unextracted seminal plasma were heated
to 90 °C for 10 min, centrifuged to remove precipi-
tated proteins, and subsequently measured in radioim-
munoassay or incubated with labelled Somatoliberin.
Heat treatment reduced dramatically the amount of
somatoliberin-like immunoreactivity of seminal
plasma (0.8 μg/l). Moreover, Somatoliberin tracer was
not degraded by coincubation with heated seminal
plasma, as shown in figure 4. No radioactive peak
eluted after the normal Somatoliberin peak; however,
another anomalous peak appeared near the void vol-
ume of the column (fig. 4), probably due to nonspe-
cific binding of Somatoliberin tracer to denatured
proteins. This suggestion was supported by the finding
that prior ultrafiltration of the heated seminal plasma,
using Centrisart I (Sartorius GmbH, G ttingen, Fed-
eral Republic of Germany; exclusion limit: Mr
= 10000-15000), led to disappearance of the first
peak of radioactivity (fig. 4). Ultrafiltered seminal
plasma contained no detectable amount (< 50 ng/l)
of somatoliberin-like immunoreactivity by radioim-
munoassay.
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Fig. 4. Sephadex G-50 fine chromatography of
[125I]somatoliberin after two days incubation at 4°C
with either unextracted seminal plasma heated at 90 °C
for 10 min (α —α) or unextracted seminal plasma heated
at 90 °C for 10 min and subsequently ultrafiltrated
(D —D). Samples were eluted with radioimmunoassay
buffer. The 1 ml fractions were directly counted in a
gamma-counter. The column void volume (V0), total
volume (Vt), and elution position of synthetic somato-
liberin are indicated by the arrows.
Discussion
Using a highly specific antibody and purified ra-
dioiodinated somatoliberin, we developed a radioim-
munoassay system able to detect 50 — 70 ng/1 soma-
toliberin. When unextracted seminal plasma was as-
sayed, high somatoliberin levels were found and di-
lution curves of synthetic somatoliberin and unex-
tracted seminal plasma ran almost completely parallel
(fig. 1). However, we found that extraction of seminal
plasma by affinity chromatography or adsorption
onto CIS Sep-pak cartridges led to disappearance of
somatoliberin-like immunoreactivity from seminal
plasma, whereas such immunoreactivity was still pres-
ent in the effluent after the adsorption step. The
Chromatographie profile of seminal plasma demon-
strated the presence of a major peak of somatoliberin-
like immunoreactivity near the void volume of the
Sephadex G-50 fine column and the complete disap-
pearance of immunoreactivity from the elution posi-
tion of somatoliberin standard (fig. 2). This peak near
the void volume of the column might be due to
aggregation forms of somatoliberin (at least 4-6
molecules, in view of the exclusion limit of the Seph-
adex column), adsorption of somatoliberin onto sem-
inal plasma proteins, or elution of degrading en-
zyme(s), which in the somatoliberin radioimmunoas-
say could cause destruction of the tracer, leading to
a misleadingly high somatoliberin concentration. The
latter hypothesis is supported by the experiment
shown in figure 3. Incubation of seminal plasma with
somatoliberin tracer led to an almost complete dis-
appearance of the peak at the void volume of the
column, thus excluding aggregation of radiolabelled
somatoliberin molecules or their binding to native
seminal plasma proteins; it also resulted in the ap-
pearance of nearly all radioactive material shortly
after the total volume of the coltnnn, as if labelled
somatoliberin were completely destroyed by an en-
zymic degrading activity present in seminal plasma.
Elution of small fragments of somatoliberin shortly
after the total volume of the column, though uncom-
mon, is not inkown. Similar effects have been reported
for other peptides. They seem to be due to interaction
of the fragments with the column packing material
(13, 14). These results demonstrate the non-identity
of somatoliberin standard with the somatoliberin-like
immunoreactivity of seminal plasma. This fact un-
derscores the notion that parallelism between stand-
ard and "unknown" in a radioimmunoassay system
is a prerequisite, but it is not sufficient to validate the
method.
Degradation of hypothalamic hormones by pepti-
dases in rat and human serum has already been re-
ported (15) and has been postulated to cause high
"blank effects" in one radioimmunoassay for soma-
tostatin (16). Nevertheless, enzymic degradation of
the tracer is probably an underestimated problem in
validating a radioimmunoassay system (17).
Rafferty & Schulster (18) found the same degradation
of labelled somatoliberin after overnight incubation
with rat plasma. However, using a Sephadex G-50
column, they found that the smaller radiolabelled
component(s) eluted before the total volume of the
column. This discrepancy with our results can be best
explained, apart from differences in the methodology,
by the different somatoliberin preparation used in the
two studies, namely somatoliberin 1—40 in Rafferty
& Schulster study (18) and somatoliberin 1-44 in
ours. Confirming previous results (18), we were also
unable to prevent somatoliberin tracer degradation
by addition of effective concentrations of protease
inhibitors like aprotinin, phenylmethylsulphonyl
fluoride, and bacitracin. However, heating seminal
plasma to 90 °C for 10 min resulted in loss of the
degradative enzymic activity of seminal plasma. The
appearance of another peak of radioactivity near the
void volume of the column is probably due to non-
specific adsorption of somatoliberin tracer to dena-
tured proteins produced by the heating'procedure.
This suggestion is supported by the fact that when
labelled somatoliberin is incubated with heated and
subsequently ultrafiltered seminal plasma, gel per-
meation chromatography shows p$ly one peak of
radioactivity coeluting with somatoliberin standard.
Moreover, somatoliberin measurement in heated sem-
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inal plasma demonstrated a dramatic reduction of
somatoliberin-likc immunoreactivity. The minimal re-
sidual somatoliberin activity is very probably due to
nonspecific binding of somatoliberin to denatured
proteins and not to residual degradative enzymic ac-
tivity. Very recently, Frohnan and coworkers (19)
described the rapid enzymic degradation of somato-
liberin to a biologically inactive product by plasma
both "bi vivo" and "in vitro" consisting of the removal
of two amino acids from the NH2-terminus. The en-
zyme(s) responsible has not yet been identified,
though a dipeptidylaminopeptidase has been sug-
gested (19). It'is tempting to speculate that the same
degradative enzymic activity is present in seminal
plasma; since the first amino acid of somatoliberin is
tyrosine, a radioiodinated dipeptide should elute near
the total volume of the Sephadex G-50 column. How-
ever, somatoliberin contains a second tyrosine residue
at position 7. If, therefore, the cleavage of the two
first amino acids at the NH2-terminus were the only
enzymic degrading activity of seminal plasma, we
should observe a second peak of radioactivity coelut-
ing near the intact somatoliberin standard and cor-
responding to labelled somatoliberin 3 — 44. It seems
likely that degradation of somatoliberin by seminal
plasma is more complete and probably leads to pro-
duction of different small fragments.
In conclusion, our study demonstrates that somato-
liberin-like immunoreactivity in seminal plasma is an
artifact due to degradative enzymic activity, which is
able to destroy radiolabelled and, probably, native
somatoliberin. It is suggested that coincubation stud-
ies of labelled substances and organic fluids must be
performed in order to reveal tracer degradation as a
source of misleading results in radioimmunoassays.
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